Alkem Laboratories Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
540 / 1328
Position in country
1899 / 4091
Net income margin, %
18.1
2.8
EBITDA margin, %
21.2
10.8
Revenue CAGR 3Y, %
11.6
8.5
Revenue Y, % chg
9.2
0.5
P/E
35.9
22.7
P/BV
5.7
1.5
P/S
4.4
2.3
EV/S
4.3
2.4
EV/EBITDA
24.8
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
-0.2
51.3
Forward P/E
26.3
15.6
Dividend Yield, %
0.9
1.7
Forward Dividend Yield, %
0
0.2
Expected dividend per share
0.5
0
Dividend Ex Date
2024-02-16
Competitors
Ranks
-
Sun Pharmaceutical Industries Ltd
00%
-
Cipla Ltd
00%
-
Torrent Pharmaceuticals Ltd
00%
-
Zydus Lifesciences Ltd
00%
-
Dr Reddy's Laboratories Ltd
00%
-
Alkem Laboratories Ltd
00%
-
Aurobindo Pharma Ltd
00%
-
IPCA Laboratories Ltd
00%
-
Lupin Ltd
00%
-
Mankind Pharma Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
India
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
6794.7
Ticker
ALKE.NS
ISIN
INE540L01014
IPO date
2015-12-23
Availability on Russian exchanges
No
Reporting for
2024-02-09
Date fact. publication of reports
2023-12-31
Company Description
Alkem Laboratories Limited is a pharmaceutical company. The Company is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates through two segments: pharmaceutical and investing. The Company produces generics, generic drugs, active pharmaceutical ingredients (APIs) and neutraceuticals, which it markets in India and approximately 50 countries internationally, primarily the United States. The Company offers various products, such as CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, among others. The Company has approximately 16 manufacturing facilities, of which 14 manufacturing facilities are at geographically diversified locations in India and two in the United States.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: